Prostate cancer

Data platform boosts publications, research, advances in treatment

Monday, May 17, 2021 - 6:32pm

"Analyzing the combined datasets increases statistical power to learn more about standard-of-care outcomes, rare adverse events, treatment effects in patient subsets, and reproducibility of results.

Key Points: 
  • "Analyzing the combined datasets increases statistical power to learn more about standard-of-care outcomes, rare adverse events, treatment effects in patient subsets, and reproducibility of results.
  • The Prostate Cancer DREAM Challenge , which generated the comprehensive dataset, attracted 50 international teams to help predict survival for prostate cancer patients and treatment discontinuation for those treated with docetaxel.
  • The Challenge produced a model that accurately predicts patient outcomes that could lead to improved clinical trial design and treatment options.\nThree years ago, the platform amassed enough data to build a portfolio of research programs.
  • Learn more here: https://www.projectdatasphere.org/events-symposia/symposium/symposium-x-...\nPDS is an independent initiative of the CEO Roundtable on Cancer, is a 501(c)(3) nonprofit corporation founded by President George H.W.

New Study Demonstrates the Clinical Utility of Predicine Liquid Biopsy Assay to Detect Copy Number Loss in Prostate Cancer

Monday, May 17, 2021 - 11:00am

b'HAYWARD, Calif., May 17, 2021 /PRNewswire-PRWeb/ --Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and Australian cohorts.\nThe study demonstrated the robust sensitivity and clinical utility of Predicine\'s cfDNA liquid biopsy assay for detecting CNVs in the PTEN-PI3K-AKT pathway in mCRPC patients.

Key Points: 
  • b'HAYWARD, Calif., May 17, 2021 /PRNewswire-PRWeb/ --Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and Australian cohorts.\nThe study demonstrated the robust sensitivity and clinical utility of Predicine\'s cfDNA liquid biopsy assay for detecting CNVs in the PTEN-PI3K-AKT pathway in mCRPC patients.
  • The study, "Plasma Cell-Free DNA Profiling of PTEN-PI3KAKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer," was published online in JCO Precision Oncology, a journal of American Society of Clinical Oncology.\nMetastatic prostate cancer is characterized by recurrent gene copy gains and deletions.
  • In particular, PTEN copy number loss is found in 40-60% of the patients.
  • Predicine has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing minimal residual disease, and early cancer detection.

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

Friday, May 14, 2021 - 5:45pm

(Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.

Key Points: 
  • (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.
  • The test uses targeted DNA and whole-transcriptome RNA sequencing to detect alterations in more than 50 genes known to be present in lung cancer.
  • The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.
  • Examples of forward-looking statements include, among others, statements regarding the ability of the Percepta Genomic Atlas to accurately detect known lung-cancer gene variants and help to guide treatment with targeted therapies.

Isoray Announces Third Quarter Fiscal 2021 Financial Results

Thursday, May 13, 2021 - 9:05pm

b'RICHLAND, Wash., May 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2021 ended March 31, 2021.\nRevenue for the third quarter of fiscal 2021 declined 10% to $2.60 million versus the record $2.88 million in the prior year comparable period.

Key Points: 
  • b'RICHLAND, Wash., May 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2021 ended March 31, 2021.\nRevenue for the third quarter of fiscal 2021 declined 10% to $2.60 million versus the record $2.88 million in the prior year comparable period.
  • However, third quarter prostate increased 7% sequentially from the second quarter of fiscal 2021.
  • Prostate brachytherapy represented 78% of total revenue for the third quarter of fiscal 2021 compared to 84% in the prior year comparable period.
  • Prostate brachytherapy represented 79% of total revenue for the first nine months of fiscal 2021 compared to 87% for the first nine months of fiscal 2020.

AIkido Pharma Inc. to Present at the Benzinga Global Small Cap Conference, the Investor Summit Group's Conference, and the LD Micro Invitational Conference

Wednesday, May 12, 2021 - 2:00pm

Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer.

Key Points: 
  • Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer.
  • We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.
  • Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.
  • The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.\n'

Avenda Health Granted FDA Breakthrough Device Designation for Technology to Treat Prostate Cancer

Tuesday, May 11, 2021 - 1:00pm

b'Breakthrough Device Designation was awarded to Avenda Health for a male \xe2\x80\x9clumpectomy\xe2\x80\x9d product in development designed to treat prostate cancer in-office while preserving quality of life.

Key Points: 
  • b'Breakthrough Device Designation was awarded to Avenda Health for a male \xe2\x80\x9clumpectomy\xe2\x80\x9d product in development designed to treat prostate cancer in-office while preserving quality of life.
  • Breakthrough Device Designation by FDA is reserved for devices that are potentially transformative, offering treatment for serious diseases that may be more effective than currently available treatments.
  • The designation may also facilitate Medicare reimbursement following FDA approval of the technology.\n\xe2\x80\x9cThe FDA has not approved a new device for the treatment of localized prostate cancer in more than 40 years.
  • \xe2\x80\x9cAvenda Health continues to advance in this mission, and the FDA\xe2\x80\x99s recognition of the incredible impact that this technology could have on the field of urology in treating prostate cancer is encouraging.\xe2\x80\x9d\nThe Avenda Health Focal Therapy System is the only artificial intelligence (AI)-enabled focal therapy system being developed to treat localized prostate cancer in a urologist\xe2\x80\x99s office under local anesthesia.

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Monday, May 10, 2021 - 12:13am

b'MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company\xe2\x80\x99s PSMA1 targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).\nThe Phase III \xe2\x80\x9cProstACT\xe2\x80\x9d trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD).

Key Points: 
  • b'MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company\xe2\x80\x99s PSMA1 targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).\nThe Phase III \xe2\x80\x9cProstACT\xe2\x80\x9d trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD).
  • The ProstACT trial will enrol approximately 390 patients and incorporates patient selection using 68Ga-PSMA imaging with TLX591-CDx (Illuccix\xc2\xae).
  • The trial will compare standard of care therapy alone versus standard of care therapy plus TLX591, with a primary endpoint of radiographic progression-free survival (rPFS).
  • ProstACT builds on a significant body of clinical data for TLX5912, which to date has been studied in over 200 patients with advanced prostate cancer, across five previous studies.

RSIP Vision Launches an Advanced AI-Based Tool for Prostate MRI and Ultrasound Registration Enabling Precise Navigation in Key Procedures

Thursday, May 6, 2021 - 2:00pm

b'RSIP Vision , an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announced today a new prostate MRI-to-ultrasound registration tool.

Key Points: 
  • b'RSIP Vision , an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announced today a new prostate MRI-to-ultrasound registration tool.
  • This provides the surgeon accurate, real-time information on regions of interest inside and near the prostate, visible mainly on the MRI scan.
  • \xe2\x80\x9cBy having RSIP Vision\xe2\x80\x99s new prostate MRI fusion tool at their fingertips, surgeons can avoid damaging sensitive internal structures.
  • During these procedures, valuable MRI information is typically not available due to the complicated nature of its acquisition in real-time.

Muno-Vax Is Focused on the Big Picture

Thursday, May 6, 2021 - 1:31pm

The Bulgarian health and wellness company has created a line of products that are designed to support the body\'s natural immune system for the long haul.

Key Points: 
  • The Bulgarian health and wellness company has created a line of products that are designed to support the body\'s natural immune system for the long haul.
  • Muno-Vax takes a different approach by making its number one objective the need to promote immune health.
  • "\nThe explanation continues by stating that the products "will keep the immune system in a constant state of excitement."
  • Its natural ingredients are designed to enrich dietary intake with substances important for a healthy prostate gland and urinary flow.

Oncologists Sound the Alarm on Drop in Cancer Screenings

Wednesday, May 5, 2021 - 6:15pm

Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.

Key Points: 
  • Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.
  • "These screenings could help detect cancer at its earliest, most treatable stage.
  • "\nDetecting cancer in the early stages, before it spreads, could make patients eligible for a non-surgical treatment option called proton therapy.\nProCure is New Jersey\'s most experienced proton therapy Center.
  • "That means fewer side effects and a lower risk of life-threatening medical issues.